The plates were developed using BCIP/ NBT and spots quantified using an Autoimmun Diagnostika GmbH Elispot plate reader (ELR07). == Prion Neutralization by Murine Immune Sera == L929 cells were co-cultured with or without 15, 1.5, or 0.15l murine Lkt-RL immune sera. PrPSc. The protein-only hypothesis anticipates that PrPScfunctions as a template to promote further misfoldings of PrPCto PrPScin an autocatalytic, self-propagating reaction.1,2At the present time, and in all species, prion diseases are fatal, untreatable neurodegenerative disorders.3 Chronic wasting disease (CWD), a prion disease of cervids, is currently the top priority animal prion disease. The progressive spread of CWD throughout North American wild cervids is of considerable concern from wildlife, economic and human health perspectives.4Given the current inability to manage CWD, in particular in wild animals, there is clear need for additional disease management tools. Historically, vaccines have been the most effective method to manage infectious diseases in both humans and animals. While developing a vaccine that targets a Indocyanine green self-protein faces many challenges, there is promising proof-of-principle evidence that such a breakthrough is achievable for PrPSc.5-12Notably, previous investigations Indocyanine green have focused primarily on overcoming immunological tolerance to achieve immune responses to PrPC.5-9,30There has been minimal consideration of pathological consequences that may be associated with the induction of PrPC-reactive antibodies. Further, these experimental vaccines often utilize adjuvants, vaccine designs, or vaccination regimes that are inconsistent with commercial vaccine production.10-12,29 While the induction of PrPCreactive antibodies has been shown to be of therapeutic benefit in delaying the onset of prion disease, there is lingering concern that these antibodies may also cause pathology. In particular, antibodies Indocyanine green to this ubiquitous cell-surface protein have been shown to cause apoptosis of neurons and disrupt immune cell signaling and function.13-16 The misfolding mechanism that makes prion diseases unique as infectious agents may represent an Achilles’ heel for the development of a safe and effective immunotherapeutic. Specifically, by targeting regions of the protein that become surface-exposed following misfolding it may be possible to develop vaccines that induce antibody responses specific to Rabbit polyclonal to TRAIL the misfolded PrPSc.17,19,23This conformation-specific approach to immunotherapy offers the potential to target pathological isomers while sparing the function of the natively structured protein. To date, 3 misfolding-specific vaccine targets, termed disease-specific epitopes (DSEs), have been identified and translated into PrPSc-specific vaccines. 17The initial YYR epitope was identified through experimental misfolding of PrPCand then, based on Indocyanine green the localization of the YYR motif to -strand 2, a YML sequence of the opposing -strand was proposed and verified as a DSE.17,18An algorithm that identifies protein regions likely to unfold proposed a DSE between -strand 2 and -helix 2.19This region, termed rigid loop (RL) is noted for its distinctive rigidity in cervids.20,21 Vaccines generated to the YYR, YML and RL DSEs have been characterized for immunogenicity, PrPSc-specificity of the induced antibodies, and safety.17Thus far only an early-generation, weakly immunogenic version of a YYR-based vaccine has been evaluated for efficacy in a challenge trial. The encouraging outcome of this trial provides impetus for further evaluation of DSE-based vaccine efficacy in clinical trials.22 In this investigation, as a strategy for prioritizing vaccines for future clinical trials, the prion neutralization capacity of antibodies specific to each of the 3 DSEs was evaluated in anin vitrocell-based assay. Antibodies to all 3 DSEs, either purified or in the context of immunoreactive sera, displayed an equivalent.